• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.

作者信息

Acar Zeydin, Kale Abdurrahman, Turgut Mehmet, Demircan Sabri, Durna Kenan, Demir Serdar, Meriç Murat, Ağaç Mustafa Tarık

出版信息

J Am Coll Cardiol. 2011 Aug 23;58(9):988-9. doi: 10.1016/j.jacc.2011.05.025.

DOI:10.1016/j.jacc.2011.05.025
PMID:21851890
Abstract
摘要

相似文献

1
Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.阿托伐他汀在保护蒽环类药物诱导的心肌病方面的疗效。
J Am Coll Cardiol. 2011 Aug 23;58(9):988-9. doi: 10.1016/j.jacc.2011.05.025.
2
The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.罗马生物医学大学校园的ARMYDA试验（阿托伐他汀用于减少血管成形术期间的心肌损伤）：原理、结果及未来展望。
Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:41-3. doi: 10.1111/j.1472-8206.2007.00539.x.
3
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.评估右丙亚胺在接受蒽环类药物治疗的癌症患者中作为心脏保护剂的作用。
Cancer Treat Rev. 2004 Nov;30(7):643-50. doi: 10.1016/j.ctrv.2004.06.002.
4
[Prevention of anthracycline cardiotoxicity].[蒽环类药物心脏毒性的预防]
Suppl Tumori. 2004 Jul-Aug;3(4):S117-9.
5
Anthracycline-induced cardiomyopathy.蒽环类药物诱导的心肌病。
Postgrad Med. 2008 Nov;120(4):67-72. doi: 10.3810/pgm.2008.11.1940.
6
Pathology of late-onset anthracycline cardiomyopathy.晚期蒽环类心肌病的病理学。
Cardiovasc Pathol. 2010 Sep-Oct;19(5):308-11. doi: 10.1016/j.carpath.2009.07.004. Epub 2009 Sep 10.
7
Pharmacologic prevention of anthracycline-induced cardiomyopathy.蒽环类药物诱导的心肌病的药物预防
Cardiol Rev. 2009 Sep-Oct;17(5):243-52. doi: 10.1097/CRD.0b013e3181b8e4c8.
8
[Promote multidisciplinary study on anthracycline-induced cardiotoxicity in children].[促进儿童蒽环类药物诱导的心脏毒性的多学科研究]
Zhonghua Er Ke Za Zhi. 2013 Aug;51(8):565-8.
9
Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.阿托伐他汀预防经皮冠状动脉介入术后程序性心肌损伤与较低水平的黏附分子有关：ARMYDA-CAMs（血管成形术期间阿托伐他汀减少心肌损伤-细胞黏附分子）子研究结果
J Am Coll Cardiol. 2006 Oct 17;48(8):1560-6. doi: 10.1016/j.jacc.2006.06.061. Epub 2006 Sep 26.
10
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.HMG CoA还原酶抑制与肥厚型心肌病患者左心室质量：一项随机安慰剂对照试验性研究
Eur J Clin Invest. 2007 Nov;37(11):852-9. doi: 10.1111/j.1365-2362.2007.01877.x.

引用本文的文献

1
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.冠状动脉钙化评分作为蒽环类药物所致心脏毒性的预测指标：ANTEC研究
Pharmaceuticals (Basel). 2025 Jul 25;18(8):1102. doi: 10.3390/ph18081102.
2
Prevention and treatment of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis of randomized controlled trials.蒽环类药物所致心脏毒性的预防与治疗：一项随机对照试验的系统评价和网状Meta分析
Cardiooncology. 2025 Jul 10;11(1):66. doi: 10.1186/s40959-025-00360-3.
3
Statins: Novel Approaches for the Management of Doxorubicin-Induced Cardiotoxicity-A Literature Review.
他汀类药物：多柔比星诱导的心脏毒性管理的新方法——文献综述
Cardiovasc Toxicol. 2025 Jul 10. doi: 10.1007/s12012-025-10030-6.
4
Randomized, Placebo-Controlled, Triple-Blind Clinical Trial of Ivabradine for the Prevention of Cardiac Dysfunction During Anthracycline-Based Cancer Therapy.伊伐布雷定预防蒽环类药物化疗期间心脏功能障碍的随机、安慰剂对照、三盲临床试验。
J Am Heart Assoc. 2025 May 20;14(10):e039745. doi: 10.1161/JAHA.124.039745. Epub 2025 May 13.
5
Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.癌症治疗相关的心脏功能障碍：预防和治疗的最新进展
Life (Basel). 2025 Mar 15;15(3):471. doi: 10.3390/life15030471.
6
Prevention of cancer-therapy related cardiac dysfunction.癌症治疗相关心脏功能障碍的预防。
Curr Heart Fail Rep. 2025 Feb 19;22(1):9. doi: 10.1007/s11897-025-00697-x.
7
Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy.阿托伐他汀与蒽环类药物化疗期间心肌细胞外容量扩张
JACC CardioOncol. 2025 Feb;7(2):125-137. doi: 10.1016/j.jaccao.2024.11.008. Epub 2025 Jan 28.
8
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity.心脏肿瘤学试验实施中的挑战：从研究他汀类药物预防蒽环类药物心脏毒性中汲取的经验教训。
Cardiooncology. 2024 Dec 18;10(1):88. doi: 10.1186/s40959-024-00292-4.
9
Deciphering the cardioprotective effects of statins in anthracycline-related cardiac dysfunction: A systematic review and meta-analysis.解读他汀类药物在蒽环类药物相关心脏功能障碍中的心脏保护作用：一项系统评价和荟萃分析。
Am J Prev Cardiol. 2024 Sep 30;20:100874. doi: 10.1016/j.ajpc.2024.100874. eCollection 2024 Dec.
10
Inflammation in Chemotherapy-Induced Cardiotoxicity.化疗诱导的心脏毒性中的炎症
Curr Cardiol Rep. 2024 Dec;26(12):1329-1340. doi: 10.1007/s11886-024-02131-5. Epub 2024 Oct 8.